321 related articles for article (PubMed ID: 10490202)
1. Pathology and behavior of small breast carcinomas.
Meyer JS; Fahrner M; Daniel FC
Semin Diagn Pathol; 1999 Aug; 16(3):257-68. PubMed ID: 10490202
[TBL] [Abstract][Full Text] [Related]
2. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
Tan P; Cady B; Wanner M; Worland P; Cukor B; Magi-Galluzzi C; Lavin P; Draetta G; Pagano M; Loda M
Cancer Res; 1997 Apr; 57(7):1259-63. PubMed ID: 9102210
[TBL] [Abstract][Full Text] [Related]
3. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome.
Lee AK; Loda M; Mackarem G; Bosari S; DeLellis RA; Heatley GJ; Hughes K
Cancer; 1997 Feb; 79(4):761-71. PubMed ID: 9024714
[TBL] [Abstract][Full Text] [Related]
4. Predictors of axillary lymph node metastasis in T1 breast carcinoma.
Shoup M; Malinzak L; Weisenberger J; Aranha GV
Am Surg; 1999 Aug; 65(8):748-52; discussion 752-3. PubMed ID: 10432085
[TBL] [Abstract][Full Text] [Related]
5. Axillary lymph node metastases associated with small invasive breast carcinomas.
Maibenco DC; Weiss LK; Pawlish KS; Severson RK
Cancer; 1999 Apr; 85(7):1530-6. PubMed ID: 10193943
[TBL] [Abstract][Full Text] [Related]
6. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
Park YH; Kim ST; Cho EY; Choi YL; Ok ON; Baek HJ; Lee JE; Nam SJ; Yang JH; Park W; Choi DH; Huh SJ; Ahn JS; Im YH
Breast Cancer Res Treat; 2010 Feb; 119(3):653-61. PubMed ID: 19957028
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Hanrahan EO; Valero V; Gonzalez-Angulo AM; Hortobagyi GN
J Clin Oncol; 2006 May; 24(13):2113-22. PubMed ID: 16648513
[TBL] [Abstract][Full Text] [Related]
8. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
9. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
10. Subpopulations of breast carcinoma defined by S-phase fraction, morphology, and estrogen receptor content.
Meyer JS; Bauer WC; Rao BR
Lab Invest; 1978 Sep; 39(3):225-35. PubMed ID: 213652
[TBL] [Abstract][Full Text] [Related]
11. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
12. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
13. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
14. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
[TBL] [Abstract][Full Text] [Related]
15. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution.
Intra M; Rotmensz N; Viale G; Mariani L; Bonanni B; Mastropasqua MG; Galimberti V; Gennari R; Veronesi P; Colleoni M; Tousimis E; Galli A; Goldhirsch A; Veronesi U
Cancer; 2004 Sep; 101(5):905-12. PubMed ID: 15329896
[TBL] [Abstract][Full Text] [Related]
17. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
18. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability.
Silverstein MJ; Gierson ED; Waisman JR; Colburn WJ; Gamagami P
J Am Coll Surg; 1995 Jun; 180(6):700-4. PubMed ID: 7773483
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients.
Rivadeneira DE; Simmons RM; Christos PJ; Hanna K; Daly JM; Osborne MP
J Am Coll Surg; 2000 Jul; 191(1):1-6; discussion 6-8. PubMed ID: 10898177
[TBL] [Abstract][Full Text] [Related]
20. Primary tumour characteristics and axillary lymph node status in breast cancer.
Yiangou C; Shousha S; Sinnett HD
Br J Cancer; 1999 Aug; 80(12):1974-8. PubMed ID: 10471048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
